Cartiva
Synthetic Cartilage Implant
The Cartiva SCI is a novel osteochondral defect repair implant with properties similar to those of cartilage, designed for the treatment of first metatarsophalangeal joint osteoarthritis.
Setting a new standard for treating hallux rididus
First new articular surface material approved by FDA in 18 years.1
The only FDA approved cartilage-like polymer.
Proven effective in the largest, longest multi-center trial ever conducted for first MTP OA.2
Study data evaluated as low risk of bias in comprehensive published review.3
Awarded the Roger A. Mann Award twice (2015 & 2017), for the best clinical research in foot and ankle.2,4
References
- Premarket Approval (PMA). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150017. Accessed on May 4, 2019.
- Baumhauer JF, Singh D, Glazebrook M, et al. Foot Ankle Int. 2016;37(5):457-469; N=130 in CARTIVA pivotal trial cohort.
- Stevens J, de Bot RT, Hermus JP, et al. JBJS reviews 5.11 (2017): e2.
- Baumhauer JF, Singh D, Glazebrook M, et al. Foot Ankle Int. 2017 Nov;38(11):1175-1182.
AP-015414